Vise Technologies Inc. Takes Position in Stryker Corporation $SYK

Vise Technologies Inc. purchased a new stake in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,844 shares of the medical technology company’s stock, valued at approximately $3,729,000.

A number of other hedge funds also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. bought a new position in Stryker in the 2nd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker in the 4th quarter worth $26,000. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter worth $27,000. Finally, Atlas Capital Advisors Inc. bought a new position in shares of Stryker during the fourth quarter valued at $27,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 665,370 shares of company stock valued at $216,238,501. Insiders own 4.60% of the company’s stock.

Stryker Trading Down 3.5%

Shares of NYSE:SYK opened at $327.97 on Friday. The stock has a market capitalization of $125.80 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock’s 50-day simple moving average is $326.64 and its two-hundred day simple moving average is $332.66. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the firm earned $3.13 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Analysts Set New Price Targets

Several research firms recently commented on SYK. Canaccord Genuity Group dropped their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. BTIG Research decreased their target price on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. Argus set a $370.00 price target on shares of Stryker in a research note on Thursday, July 9th. Finally, BMO Capital Markets started coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.